Related Experiment Video
Updated: Aug 15, 2025
06:02
An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
Published on: November 2, 2020
5.8K
Multi-modality management of hypertrophic cardiomyopathy
Shiavax J Rao1, Shaikh B Iqbal1, Arjun S Kanwal2
1Department of Medicine, MedStar Union Memorial Hospital, Baltimore, USA.
Hospital Practice (1995)
|January 4, 2023
Summary
Hypertrophic cardiomyopathy (HCM) management is evolving with new invasive and pharmacologic options. Personalized treatment combining these strategies is crucial due to HCM
Area of Science:
- Cardiology
- Genetics
- Pharmacology
Background:
- Hypertrophic cardiomyopathy (HCM) is an inherited condition causing left ventricular thickening.
- Obstructive HCM is defined by a significant pressure gradient, impacting treatment decisions.
Purpose of the Study:
- To review current and emerging invasive and pharmacotherapeutic options for managing hypertrophic cardiomyopathy.
- To highlight the need for individualized treatment strategies in HCM patients.
Main Methods:
- Review of established and novel invasive therapies (e.g., septal myectomy, alcohol septal ablation, MitraClip).
- Discussion of evolving pharmacological treatments, including conventional drugs and novel myosin inhibitors like Mavacamten.
Main Results:
- Significant expansion in both invasive and pharmacologic treatment options for HCM.
- Mavacamten and other myosin inhibitors show promise in changing disease management.
- Phenotypic variability necessitates tailored, combination treatment approaches.
Conclusions:
- Current guidelines advocate for integrated invasive and non-invasive strategies for HCM.
- Individualized management is key due to the diverse clinical presentations of HCM.
- Novel therapies offer new hope for improving outcomes in hypertrophic cardiomyopathy patients.
Related Concept Videos
01:29Cardiomyopathy V: Interprofessional Care
25
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
25
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
30
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
30
01:30Cardiomyopathy II: Dilated Cardiomyopathy
19
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
19
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
17
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
17
01:30Heart Failure V: Medical Management
19
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
19
01:14Myocarditis III: Medical Management
13
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
13